User menu

Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function

Bibliographic reference Flanagan, Shawn ; McKee, Edward E ; Das, Debaditya ; Tulkens, Paul M. ; Hosako, Hiromi ; et. al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. In: Antimicrobial Agents and Chemotherapy, Vol. 59, no.1, p. 178-185 (2015)
Permanent URL
  1. Barnhill A. E., Brewer M. T., Carlson S. A., Adverse Effects of Antimicrobials via Predictable or Idiosyncratic Inhibition of Host Mitochondrial Components, 10.1128/aac.00678-12
  2. Nagiec E. E., Wu L., Swaney S. M., Chosay J. G., Ross D. E., Brieland J. K., Leach K. L., Oxazolidinones Inhibit Cellular Proliferation via Inhibition of Mitochondrial Protein Synthesis, 10.1128/aac.49.9.3896-3902.2005
  3. Hirano M., Palenzuela L., Hahn N. M., Nelson R. P., Arno J. N., Schobert C., Bethel R., Ostrowski L. A., Sharma M. R., Datta P. P., Agrawal R. K., Schwartz J. E., Does Linezolid Cause Lactic Acidosis by Inhibiting Mitochondrial Protein Synthesis?, 10.1086/430441
  4. Garrabou G., Soriano A., Lopez S., Guallar J. P., Giralt M., Villarroya F., Martinez J. A., Casademont J., Cardellach F., Mensa J., Miro O s., Reversible Inhibition of Mitochondrial Protein Synthesis during Linezolid-Related Hyperlactatemia, 10.1128/aac.01190-06
  5. Gerson S. L., Kaplan S. L., Bruss J. B., Le V., Arellano F. M., Hafkin B., Kuter D. J., Hematologic Effects of Linezolid: Summary of Clinical Experience, 10.1128/aac.46.8.2723-2726.2002
  6. Javaheri M, Khurana R N, O'Hearn T M, Lai M M, Sadun A A, Linezolid-induced optic neuropathy: a mitochondrial disorder?, 10.1136/bjo.2006.102541
  7. Joshi Lavnish, Taylor Simon R. J., Large Oliver, Yacoub Sophie, Lightman Susan, A Case of Optic Neuropathy after Short‐Term Linezolid Use in a Patient with Acute Lymphocytic Leukemia, 10.1086/597298
  8. Metaxas Eugenios I, Falagas Matthew E, Update on the safety of linezolid, 10.1517/14740330903049706
  9. Narita Masashi, Tsuji Brian T, Yu Victor L, Linezolid-Associated Peripheral and Optic Neuropathy, Lactic Acidosis, and Serotonin Syndrome, 10.1592/phco.27.8.1189
  10. Apodaca Aaron A., Rakita Robert M., Linezolid-Induced Lactic Acidosis, 10.1056/nejm200301023480123
  11. De Vriese A. S., Van Coster R., Smet J., Seneca S., Lovering A., Van Haute L. L., Vanopdenbosch L. J., Martin J.-J., Ceuterick-de Groote C., Vandecasteele S., Boelaert J. R., Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis, 10.1086/501356
  12. Cohen Bruce H., Saneto Russell P., Mitochondrial translational inhibitors in the pharmacopeia, 10.1016/j.bbagrm.2012.02.023
  13. Sotgiu Giovanni, Centis Rosella, D'Ambrosio Lia, Alffenaar Jan-William C., Anger Holly A., Caminero Jose A., Castiglia Paolo, De Lorenzo Saverio, Ferrara Giovanni, Koh Won-Jung, Schecter Giesela F., Shim Tae S., Singla Rupak, Skrahina Alena, Spanevello Antonio, Udwadia Zarir F., Villar Miquel, Zampogna Elisabetta, Zellweger Jean-Pierre, Zumla Alimuddin, Migliori Giovanni Battista, Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis, 10.1183/09031936.00022912
  14. Vinh Donald C., Rubinstein Ethan, Linezolid: a review of safety and tolerability, 10.1016/s0163-4453(09)60009-8
  15. Chao C-C, Sun H-Y, Chang Y-C, Hsieh S-T, Painful neuropathy with skin denervation after prolonged use of linezolid, 10.1136/jnnp.2007.127910
  16. Beekmann Susan E., Gilbert David N., Polgreen Philip M., Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey, 10.1016/j.diagmicrobio.2008.08.009
  17. Azamfirei Leonard, Copotoiu Sanda-Maria, Branzaniuc Klara, Szederjesi Janos, Copotoiu Ruxandra, Berteanu Cristina, Complete blindness after optic neuropathy induced by short-term linezolid treatment in a patient suffering from muscle dystrophy, 10.1002/pds.1320
  18. Pharmacia and Upjohn Co, Zyvox (linezolid) injection, tablets and oral suspension (prescribing information) (2014)
  19. Yum J. H., Choi S. H., Yong D., Chong Y., Im W. B., Rhee D.-K., Lee K., Comparative In Vitro Activities of Torezolid (DA-7157) against Clinical Isolates of Aerobic and Anaerobic Bacteria in South Korea, 10.1128/aac.00728-10
  20. Brown S. D., Traczewski M. M., Comparative In Vitro Antimicrobial Activities of Torezolid (TR-700), the Active Moiety of a New Oxazolidinone, Torezolid Phosphate (TR-701), Determination of Tentative Disk Diffusion Interpretive Criteria, and Quality Control Ranges, 10.1128/aac.01569-09
  21. Prokocimer P., Bien P., DeAnda C., Pillar C. M., Bartizal K., In Vitro Activity and Microbiological Efficacy of Tedizolid (TR-700) against Gram-Positive Clinical Isolates from a Phase 2 Study of Oral Tedizolid Phosphate (TR-701) in Patients with Complicated Skin and Skin Structure Infections, 10.1128/aac.00458-12
  22. Locke J. B., Morales G., Hilgers M., G. C. K., Rahawi S., Jose Picazo J., Shaw K. J., Stein J. L., Elevated Linezolid Resistance in Clinical cfr-Positive Staphylococcus aureus Isolates Is Associated with Co-Occurring Mutations in Ribosomal Protein L3, 10.1128/aac.00714-10
  23. Ong V., Flanagan S., Fang E., Dreskin H. J., Locke J. B., Bartizal K., Prokocimer P., Absorption, Distribution, Metabolism, and Excretion of the Novel Antibacterial Prodrug Tedizolid Phosphate, 10.1124/dmd.113.056697
  24. Scatena Roberto, Mitochondria and Drugs, Advances in Experimental Medicine and Biology (2012) ISBN:9789400728684 p.329-346, 10.1007/978-94-007-2869-1_15
  25. Prokocimer Philippe, De Anda Carisa, Fang Edward, Mehra Purvi, Das Anita, Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections : The ESTABLISH-1 Randomized Trial, 10.1001/jama.2013.241
  26. Moran Gregory J, Fang Edward, Corey G Ralph, Das Anita F, De Anda Carisa, Prokocimer Philippe, Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial, 10.1016/s1473-3099(14)70737-6
  27. Flanagan S , McKee EE , Das D , Tulkens PM , Hosako H , Fiedler-Kelly J , Passarell J , Radovsky A , Prokocimer P . 2012. Abstr 52nd Int Conf Antimicrob Agents Chemother, 9 to 12 September 2012, San Francisco, CA, abstr A-1291.
  28. Flanagan S , McKee EE , Das D , Tulkens PM , Hosako H , Fiedler-Kelly J , Passarell J , Radovsky A , Prokocimer P . 2013. Abstr 53rd Int Conf Antimicrob Agents Chemother, 10 to 13 September 2013, Denver, CO, abstr A-017b.
  29. Flanagan S , McKee EE , Das D , Tulkens PM , Hosako H , Fiedler-Kelly J , Passarell J , Radovsky A , Prokocimer P . 2014. Abstr 53rd Annu Meet Soc Toxicol, 23 to 27 March 2014, Phoenix, AZ, abstr 1634.
  30. McKee, Am J Physiol, 258, E492 (1990)
  31. Lemaire S., Van Bambeke F., Appelbaum P. C., Tulkens P. M., Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines, 10.1093/jac/dkp267
  32. Housman S. T., Pope J. S., Russomanno J., Salerno E., Shore E., Kuti J. L., Nicolau D. P., Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers, 10.1128/aac.05354-11
  33. Lemaire S., Tulkens P. M., Van Bambeke F., Cellular Pharmacokinetics of the Novel Biaryloxazolidinone Radezolid in Phagocytic Cells: Studies with Macrophages and Polymorphonuclear Neutrophils, 10.1128/aac.01723-09
  34. Tulkens P. M., Intracellular distribution and activity of antibiotics, 10.1007/bf01964420
  35. Shinabarger Dean, Mechanism of action of the oxazolidinone antibacterial agents, 10.1517/13543784.8.8.1195
  36. Flanagan S , Minassian SL , Muñoz KA , Dreskin H , Fang E , Prokocimer P . 2013. Lack of pharmacokinetic drug interaction of tedizolid phosphate with pseudoephedrine in healthy subjects, poster 921. 23rd Eur Congr Clin Microbiol Infect Dis, Berlin, Germany.
  37. Abe Sadahiro, Chiba Koji, Cirincione Brenda, Grasela Thaddeus H., Ito Kaori, Suwa Toshio, Population Pharmacokinetic Analysis of Linezolid in Patients With Infectious Disease: Application to Lower Body Weight and Elderly Patients, 10.1177/0091270009337947
  38. Flanagan S., Passarell J., Lu Q., Fiedler-Kelly J., Ludwig E., Prokocimer P., Tedizolid Population Pharmacokinetics, Exposure Response, and Target Attainment, 10.1128/aac.03423-14
  39. Matsumoto Kazuaki, Shigemi Akari, Takeshita Ayumi, Watanabe Erika, Yokoyama Yuta, Ikawa Kazuro, Morikawa Norifumi, Takeda Yasuo, Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients, 10.1016/j.ijantimicag.2014.05.010
  40. Dong H.-Y., Xie J., Chen L.-H., Wang T.-T., Zhao Y.-R., Dong Y.-L., Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients, 10.1007/s10096-013-2041-3
  41. Cattaneo Dario, Orlando Giovanna, Cozzi Valeria, Cordier Laura, Baldelli Sara, Merli Stefania, Fucile Serena, Gulisano Cecilia, Rizzardini Giuliano, Clementi Emilio, Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections, 10.1016/j.ijantimicag.2013.02.020
  42. Pea F., Viale P., Cojutti P., Del Pin B., Zamparini E., Furlanut M., Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients, 10.1093/jac/dks153
  43. Brown AN , Louie A , Adams J , Jambunathan K , Baluya D , Hafner R , Drusano GL . 2014. Relationship between linezolid (LZD) exposure profiles and toxicity in the hollow fiber infection model (HFIM) system, poster A-026b. Abstr 54th Intersci Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC.
  44. Louie A., Liu W., Kulawy R., Drusano G. L., In Vivo Pharmacodynamics of Torezolid Phosphate (TR-701), a New Oxazolidinone Antibiotic, against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Strains in a Mouse Thigh Infection Model, 10.1128/aac.01565-10
  45. Lin, Antimicrob Agents Chemother, 41, 2127 (1997)
  46. Andes D., van Ogtrop M. L., Peng J., Craig W. A., In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid), 10.1128/aac.46.11.3484-3489.2002
  47. Morata L., Cuesta M., Rojas J. F., Rodriguez S., Brunet M., Casals G., Cobos N., Hernandez C., Martinez J. A., Mensa J., Soriano A., Risk Factors for a Low Linezolid Trough Plasma Concentration in Acute Infections, 10.1128/aac.01694-12
  48. Flanagan Shawn D., Bien Paul A., Muñoz Kelly A., Minassian Sonia L., Prokocimer Philippe G., Pharmacokinetics of Tedizolid Following Oral Administration: Single and Multiple Dose, Effect of Food, and Comparison of Two Solid Forms of the Prodrug, 10.1002/phar.1337
  49. Plock N., Buerger C., Joukhadar C., Kljucar S., Kloft C., Does Linezolid Inhibit Its Own Metabolism? Population Pharmacokinetics As a Tool to Explain the Observed Nonlinearity in Both Healthy Volunteers and Septic Patients, 10.1124/dmd.106.013755
  50. Meagher A. K., Forrest A., Rayner C. R., Birmingham M. C., Schentag J. J., Population Pharmacokinetics of Linezolid in Patients Treated in a Compassionate-Use Program, 10.1128/aac.47.2.548-553.2003
  51. Antal E , Grasela T , Bergstrom T , Bruss J , Wong E . 2000. The role of population PK/PD analysis during the implementation of a bridging strategy for linezolid, poster P-16. 36th Drug Info Assoc (DIA) Meet, Hong Kong, People's Republic of China, 16 to 19 November 2000.
  52. FDA, New drug applications 21-130, 21-131, 21-132 ZyvoxTM (linezolid). Appendix A, preclinical summary, part II (2000)
  53. Cubist Pharmaceuticals. 2014. NDA 205435 NDA 205436. Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections. Anti Infect Drugs Advis Comm Meet, 31 March 2014.
  54. Bernstein Wendy B, Trotta Richard F, Rector James T, Tjaden Jeffery A, Barile Anthony J, Mechanisms for Linezolid-Induced Anemia and Thrombocytopenia, 10.1345/aph.1c361
  55. Lodise T. P., Fang E., Minassian S. L., Prokocimer P. G., Platelet Profile in Patients with Acute Bacterial Skin and Skin Structure Infections Receiving Tedizolid or Linezolid: Findings from the Phase 3 ESTABLISH Clinical Trials, 10.1128/aac.03509-14
  56. Pacheu-Grau D., Gomez-Duran A., Iglesias E., Lopez-Gallardo E., Montoya J., Ruiz-Pesini E., Mitochondrial antibiograms in personalized medicine, 10.1093/hmg/dds517
  57. Colca Jerry R., McDonald William G., Waldon Daniel J., Thomasco Lisa M., Gadwood Robert C., Lund Eric T., Cavey Gregory S., Mathews W. Rodney, Adams Lonnie D., Cecil Eric T., Pearson James D., Bock Jeffrey H., Mott John E., Shinabarger Dean L., Xiong Liqun, Mankin Alexander S., Cross-linking in the Living Cell Locates the Site of Action of Oxazolidinone Antibiotics, 10.1074/jbc.m302109200
  58. National Research Council, Guide for the care and use of laboratory animals (1996)
  59. Shaw K. J., Poppe S., Schaadt R., Brown-Driver V., Finn J., Pillar C. M., Shinabarger D., Zurenko G., In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains, 10.1128/aac.00859-08
  60. Leach Karen L., Swaney Steven M., Colca Jerry R., McDonald William G., Blinn James R., Thomasco Lisa M., Gadwood Robert C., Shinabarger Dean, Xiong Liqun, Mankin Alexander S., The Site of Action of Oxazolidinone Antibiotics in Living Bacteria and in Human Mitochondria, 10.1016/j.molcel.2007.04.005
  61. McKee E. E., Ferguson M., Bentley A. T., Marks T. A., Inhibition of Mammalian Mitochondrial Protein Synthesis by Oxazolidinones, 10.1128/aac.01411-05